Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.51 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.51 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.51 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.51 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | HRH2 | P25021 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051128 | 0.98 | LMNA (0.55) | LMNAPOLBGAAMAPTTSHR | |
| SCHEMBL306889 | 0.98 | LMNA (0.55) | LMNAPOLBGAAMAPTTSHR | |
| SCHEMBL306888 | 0.98 | LMNA (0.55) | LMNAPOLBGAAMAPTTSHR | |
| Hydrochloric Acid SCHEMBL27632975 | 0.96 | LMNA (0.54) | LMNAPOLBGAAMAPTTSHR | |
| Hydrochloric Acid SCHEMBL942873 | 0.96 | LMNA (0.54) | LMNAPOLBGAAMAPTTSHR | |
| Hydrochloric Acid SCHEMBL1032722 | 0.96 | LMNA (0.54) | LMNAPOLBGAAMAPTTSHR | |
| Bromide SCHEMBL16061698 | 0.95 | LMNA (0.53) | LMNAPOLBGAAMAPTTSHR | |
| Cadaverine Tartrate SCHEMBL3998786 | 0.83 | LMNA (0.47) | LMNAPOLBGAAMAPTTSHR | |
| Cadaverine Tartrate SCHEMBL28359878 | 0.83 | LMNA (0.47) | LMNAPOLBGAAMAPTTSHR | |
| Cadaverine Tartrate SCHEMBL307192 | 0.82 | LMNA (0.46) | LMNAPOLBGAAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220060-B1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES | MOTAC NEUROSCIENCE LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-8389555-B2 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-20110046153-A1 | Medicaments | MOTAC NEUROSCIENCE LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2220060-A1 | MEDICAMENTS | Motac Neuroscience Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009056805-A1 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-7524871-B2 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY (SI) | 2009-04-28 | — | — | US | disclosed |
| EP-1562921-B1 | PROCESS FOR PREPARING 2,6-DIAMINO-4,5,6,7-TETRAHYDRO-BENZOTHIAZOLE | CIPLA LTD (IN) | 2008-05-21 | — | — | EP | disclosed |
| EP-1562921-B1 | PROCESS FOR PREPARING 2,6-DIAMINO-4,5,6,7-TETRAHYDRO-BENZOTHIAZOLE | CIPLA LTD (IN) | 2008-05-21 | — | — | EP | disclosed |
| US-7285669-B2 | Process for preparing 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole | CIPLA LIMITED (IN) | 2007-10-23 | — | — | US | disclosed |
| US-7285669-B2 | Process for preparing 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole | CIPLA LIMITED (IN) | 2007-10-23 | — | — | US | disclosed |
| US-20030191139-A1 | Thrombin inhibitors | UNIVERSITY OF LJUBLJANA (SI) | 2003-10-09 | — | — | US | disclosed |
| WO-2003048155-A1 | THROMBIN INHIBITORS | UNIVERSITY OF LJUBLJANA (SI) | 2003-06-12 | — | — | WO | disclosed |
| EP-1287018-A2 | THROMBIN INHIBITORS | Lek Pharmaceutical and Chemical Co. D.D. (SI) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001085760-A1 | THROMBIN INHIBITORS | LEK PHARMACEUTICAL & CHEMICAL CO. DD (SI) | 2001-11-15 | — | — | WO | disclosed |
| EP-0483252-A1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES FOR TREATING DISEASES OF THE EYE | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
| WO-1991001136-A1 | TETRAHYDROBENZOTHIAZOLE DERIVATIVES FOR TREATING DISEASES OF THE EYE | BOEHRINGER INGELHEIM KG (DE) | 1991-02-07 | — | — | WO | disclosed |
| US-4886812-A | REGULATING DOPAMINE CONCENTRATION; PARKINSON DISEASE, HYPOTENSIVE AGENT, SCHIZOPHRENIA | DR. KARL THOMAE GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| US-4843086-A | HYPOTENSIVE AGENTS, SCHIZOPHRENIA, PARKINSON'S DISEASE | BOEHRINGER INGELHEIM KG (DE) | 1989-06-27 | — | — | US | disclosed |
| US-4731374-A | PARKINSON*S DISEASE | DR. KARL THOMAE GMBH (DE) | 1988-03-15 | — | — | US | disclosed |
| EP-0186087-A1 | Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs | Dr. Karl Thomae GmbH (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191139-A1 | Thrombin inhibitors | TFPI, F2, SERPINC1 | ADRA2A 2630/4885ADRB2 1475/4885HTR1A 911/4885 |
| US-20110046153-A1 | Medicaments | MTNR1A, SIGMAR1, OPRK1 | ADRA2A 18/4885ADRB2 11/4885HTR1A 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.